Payment overview · 2025
General Payments
$92.93
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brian E. Edwards, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASHEVILLE, NC · NPI 1376679571
Verified facts
What the public records show
CMS Open Payments records show Brian E. Edwards, MD received $92.93 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 79.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.08 | 79.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 20.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $74.08 | 1 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 88 |
| Lisinopril | Lisinopril | 212 | 66 |
| Losartan Potassium | Losartan Potassium | 203 | 55 |
| Omeprazole | Omeprazole | 192 | 59 |
| Eliquis | Apixaban | 186 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 54 |
| Alprazolam | Alprazolam | 151 | 37 |
| Furosemide | Furosemide | 150 | 50 |
| Gabapentin | Gabapentin | 138 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 41 |
| Carvedilol | Carvedilol | 132 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 126 | 40 |
| Simvastatin | Simvastatin | 126 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 45 |
| Trazodone Hcl | Trazodone Hcl | 121 | 31 |
| Famotidine | Famotidine | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 37 |
| Metformin Hcl | Metformin Hcl | 107 | 32 |
| Celecoxib | Celecoxib | 100 | 44 |
| Sertraline Hcl | Sertraline Hcl | 96 | 28 |
| Metformin Hcl Er | Metformin Hcl | 91 | 33 |
| Telmisartan | Telmisartan | 91 | 32 |
| Allopurinol | Allopurinol | 90 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 28 |
| Spironolactone | Spironolactone | 84 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 30 |
| Ezetimibe | Ezetimibe | 83 | 27 |
| Synthroid | Levothyroxine Sodium | 80 | 23 |
| Prednisone | Prednisone | 79 | 57 |
| Jardiance | Empagliflozin | 78 | 14 |
| Lorazepam | Lorazepam | 77 | 23 |
| Alendronate Sodium | Alendronate Sodium | 75 | 22 |
| Potassium Chloride | Potassium Chloride | 73 | 27 |
| Clonazepam | Clonazepam | 62 | 13 |
| Meloxicam | Meloxicam | 59 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 20 |
| Xarelto | Rivaroxaban | 55 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 17 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 50 | 50 |
| Atenolol | Atenolol | 49 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Valsartan | Valsartan | 45 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Ozempic | Semaglutide | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | 22 |
| Estradiol | Estradiol | 41 | 18 |
| Valacyclovir | Valacyclovir Hcl | 41 | 17 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 15 |
| Finasteride | Finasteride | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 22 |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 14 |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 16 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.93 · 2 records | AstraZeneca Pharmaceuticals LP | JARDIANCE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error